

Freedom of Information Request: Our Reference CTMUHB_586_25

You asked:

Q1. How many new patients were treated for Asthma by the Trust's Respiratory Department in the latest 4 month period (August - November 2025) with the treatments I have provided below?

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments either in or before March 2025, they can be classed as a new patient for the purposes of this question.

- Cinquaero (Reslizumab)
- Dupixent (Dupilumab)
- Fasentra (Benralizumab)
- Nucala (Mepolizumab)
- Tezpire (Tezepelumab)
- Xolair (Omalizumab)

Q2. How many new patients were treated for Chronic Obstructive Pulmonary Disease (COPD) by the Trust's Respiratory Department in the latest 4-month period (August – November 2025) with the treatments I have provided below?

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments either in or before March 2025, they can be classed as a new patient for the purposes of this question.

- Dupixent (Dupilumab)
- Nucala (Mepolizumab)

Our response:

Unfortunately, we are unable to identify the number of "new patients" or those specifically treated for Asthma or Chronic Obstructive Pulmonary Disease (COPD), as this detailed information is not recorded within our Medicines Management electronic system.

We therefore confirm that the Health Board does not centrally record this specific information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.